Proactive Investors - Run By Investors For Investors

OptiBiotix Health signs Russia and Kazakhstan distribution deal

The company is teaming up with SilvExpo, a local pharmaceutical and nutraceutical business
st basil's moscow
Dawning opportunity: The Russian probiotics market on its own is estimated by the firm to be worth €340mln

OptiBiotix Health plc (LON:OPTI) has inked a distribution agreement that will see its cholesterol and blood pressure product sold in Russia and Kazakhstan.

In the latest of a series of similar commercial deals, the company is teaming up with SilvExpo, a local pharmaceutical and nutraceutical business.

WATCH: OptiBiotix’s SlimBiome gathers steam as subsidiary eyes potential IPO

OptiBiotix’s probiotic CholBiomeX3, containing the LPLDL bacteria strain, will be stocked in pharmacies in the two countries.

The Russian probiotics market on its own is estimated by the firm to be worth €340mln, and is growing at 10% annually.

"We are pleased to announce this agreement which extends the sales channel of our CholBiome products into Russia and Kazakhstan where cardiovascular disease are the leading cause of morbidity and mortality,” said commercial director Per Rehné.

“We chose SilvExpo for its knowledge and speed to market and they have shown the ability to grow product sales in challenging markets.

“This agreement is a strategic step to build the distribution sales channel for CholBiome products in Eastern Europe and we anticipate that the agreement could produce revenues quickly."

On Monday, OptiBiotix, which is developing probiotic treatments for weight loss and diabetes as well as cholesterol lowering products, signed its ninth distribution customer for the SlimBiome range.

View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Articles

scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
Widecells
September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
myLotus testing kit
October 31 2018
The launch at the Fertility Show in London at the start of November is the first step in a switch in focus brought about by new executive chairman Matthew Walls

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use